PL3180329T3 - Triazole jako inhibitory receptora NR2B - Google Patents

Triazole jako inhibitory receptora NR2B

Info

Publication number
PL3180329T3
PL3180329T3 PL15777754T PL15777754T PL3180329T3 PL 3180329 T3 PL3180329 T3 PL 3180329T3 PL 15777754 T PL15777754 T PL 15777754T PL 15777754 T PL15777754 T PL 15777754T PL 3180329 T3 PL3180329 T3 PL 3180329T3
Authority
PL
Poland
Prior art keywords
triazoles
receptor inhibitors
nr2b receptor
nr2b
inhibitors
Prior art date
Application number
PL15777754T
Other languages
English (en)
Polish (pl)
Inventor
Rudolf Schindler
Hans-Joachim Lankau
Norbert Höfgen
Ute Egerland
Barbara Langen
Rita Dost
Simon Ward
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of PL3180329T3 publication Critical patent/PL3180329T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15777754T 2014-08-15 2015-08-14 Triazole jako inhibitory receptora NR2B PL3180329T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462037831P 2014-08-15 2014-08-15
US201562146656P 2015-04-13 2015-04-13
PCT/US2015/045412 WO2016025917A1 (en) 2014-08-15 2015-08-14 Triazoles as nr2b receptor inhibitors
EP15777754.1A EP3180329B1 (en) 2014-08-15 2015-08-14 Triazoles as nr2b receptor inhibitors

Publications (1)

Publication Number Publication Date
PL3180329T3 true PL3180329T3 (pl) 2020-08-24

Family

ID=54266608

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15777754T PL3180329T3 (pl) 2014-08-15 2015-08-14 Triazole jako inhibitory receptora NR2B

Country Status (9)

Country Link
US (2) US9981950B2 (cg-RX-API-DMAC7.html)
EP (1) EP3180329B1 (cg-RX-API-DMAC7.html)
JP (1) JP6605020B2 (cg-RX-API-DMAC7.html)
DK (1) DK3180329T3 (cg-RX-API-DMAC7.html)
ES (1) ES2791186T3 (cg-RX-API-DMAC7.html)
HU (1) HUE049277T2 (cg-RX-API-DMAC7.html)
PL (1) PL3180329T3 (cg-RX-API-DMAC7.html)
PT (1) PT3180329T (cg-RX-API-DMAC7.html)
WO (1) WO2016025917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途
IL267195B2 (en) 2016-12-14 2024-05-01 Sk Biopharmaceuticals Co Ltd Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
JP7346441B2 (ja) 2018-04-04 2023-09-19 ヤンセン ファーマシューティカ エヌ.ベー. 置換ピリジン及びピリミジン並びにglun2b受容体調節物質としてのそれらの使用
MX2021015500A (es) 2019-06-14 2022-02-10 Janssen Pharmaceutica Nv Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
CA3142998A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as glun2b receptor modulators
TW202112774A (zh) 2019-06-14 2021-04-01 比利時商健生藥品公司 經取代之吡唑并-吡啶醯胺及其作為glun2b受體調節劑之用途
JP2022536424A (ja) 2019-06-14 2022-08-16 ヤンセン ファーマシューティカ エヌ.ベー. 置換ヘテロ芳香族ピラゾロピリジン及びglun2b受容体調節因子としてのそれらの使用
KR20220020917A (ko) 2019-06-14 2022-02-21 얀센 파마슈티카 엔.브이. 치환된 피라졸로[4,3-b]피리딘 및 GLUN2B 수용체 조절제로서의 이들의 용도
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610723B2 (en) * 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
EP1490364B1 (en) 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
TW200604183A (en) 2004-02-18 2006-02-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
RU2499598C2 (ru) 2008-03-27 2013-11-27 Евотек Интернациональ Гмбх Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов
WO2010016490A1 (ja) 2008-08-05 2010-02-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
WO2010108187A2 (en) * 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
USRE49517E1 (en) 2014-08-15 2023-05-02 Janssen Pharmaceuticals, Inc. Pyrazoles
HRP20200410T1 (hr) 2015-07-09 2020-08-21 Janssen Pharmaceutica Nv Supstituirani 4-azaindoli i njihova upotreba kao modulatora glun2b receptora
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途

Also Published As

Publication number Publication date
ES2791186T3 (es) 2020-11-03
US9981950B2 (en) 2018-05-29
WO2016025917A1 (en) 2016-02-18
US10323021B2 (en) 2019-06-18
HUE049277T2 (hu) 2020-09-28
JP2017524019A (ja) 2017-08-24
US20180282305A1 (en) 2018-10-04
US20170226087A1 (en) 2017-08-10
EP3180329A1 (en) 2017-06-21
DK3180329T3 (da) 2020-04-06
JP6605020B2 (ja) 2019-11-13
EP3180329B1 (en) 2020-03-18
PT3180329T (pt) 2020-06-08

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL251071A0 (en) Benzyl-substituted indazoles as bub1 inhibitors
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
HUE049277T2 (hu) Triazolok mint NR2B receptor inhibitorok
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
IL246555A0 (en) Indazole compounds as irak4 inhibitors
GB201411344D0 (en) Cloning
AP2016009496A0 (en) Substituted spirocydic inhibitors of autotaxin
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
HUE036810T2 (hu) Elrendezés jármû ajtajának nyitására
PL3122667T3 (pl) Jednostka podająca
GB201405651D0 (en) Delivering an action
HUE040138T2 (hu) Adagolóegység
IL250306A0 (en) indazoles
PL3122666T3 (pl) Podający zespół
PL3122664T3 (pl) Jednostka doprowadzająca
HK1237771A1 (en) Triazoles as nr2b receptor inhibitors
AU5514P (en) FT01 Trachelospermum asiaticum
GB201418154D0 (en) Inhibitors
AU2014301V (en) SJ01 Trachelospermum asiaticum
GB201405343D0 (en) Feed unit